hotspot -WSS

hotspot

author：fashion 2025-09-03 11:51:22 - browse：49

glum Benjamin — health insurance coverage from STAT — Adobe

Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences.

Scion was started by former Apple Tree Partners colleagues Sam Hall and Aaron Kantoff, along with Tadd Wessel, managing partner of the health care private equity firm Petrichor. They raised $310 million for its first fund, blowing past their original $250 million target.

They’re planning on taking a different tack with biotech venture capital. For starters, Scion plans to work on a significantly longer timeframe. Most firms in existence today write checks, help investments grow, and find a way to recoup their money in a 10-year timeframe. Scion is doubling that, setting a 20-year plan for its first fund.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： FDA approves world's first CRISPR

explore

WSS

STAT letters to the editor on burnt

Mitch McConnell episode has important public health takeaway

Trump indictment: Who are the 'co

Patients' immediate access to test results puts radiologists in a bind

Pharma patents targeted by Biden in move to slash drug prices

Scientists inch closer to single

explore

hotspot

focus

Novavax promises a turnaround & Lilly roils the obesity market

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Walensky prepares to leave CDC — and Congress — behind

NIH launches clinical trials and new research office for long Covid

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Trump demands the U.S. pay no more for drugs than other countries … again

After sickle

Novavax promises a turnaround & Lilly roils the obesity market

No plane should take off without an EpiPen onboard

focus

FDA needs staff influx to meet gene therapy needs, Marks says

New safety details link Apellis eye drug to rare cases of blindness

Radiology is caught between AI's potential and concern for patients

What causes an itch? Researchers may have solved the mystery

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

What PEPFAR has meant on the ground in Ukraine

explore

leisure time

focus

hotspot